Summary Summary We used functional
We used functional magnetic resonance imaging to investigate magnetic resonance imaging to investigate the effects of short-term treatment with the effects of short-term treatment with reboxetine, a selective noradrenaline reboxetine, a selective noradrenaline reuptake inhibitor, on emotional facial reuptake inhibitor, on emotional facial processing in healthy volunteers. processing in healthy volunteers. Reboxetine was associated with a reduced Reboxetine was associated with a reduced amygdala response to fearful faces and amygdala response to fearful faces and increased activation to happy increased activation to happy v.
v. neutral neutral facial expressions in the right fusiform facial expressions in the right fusiform gyrus, relative to placebo treatment and in gyrus, relative to placebo treatment and in the absence of changes in mood.Our the absence of changes in mood.Our results show that reboxetine modulates results show that reboxetine modulates the neural substrates of emotional the neural substrates of emotional processing, highlighting a mechanism by processing, highlighting a mechanism by which drug treatment could normalise which drug treatment could normalise negative bias in depression and anxiety. negative bias in depression and anxiety.
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Cognitive theories of depression emphasise
Cognitive theories of depression emphasise the role of negative biases in information the role of negative biases in information processing as key to the aetiology and processing as key to the aetiology and maintenance of depression. In contrast, maintenance of depression. In contrast, neurobiological theories assert that depresneurobiological theories assert that depression is caused by an imbalance in key sion is caused by an imbalance in key neurotransmitters, which can be addressed neurotransmitters, which can be addressed using pharmacotherapy. However, the using pharmacotherapy. However, the mechanisms by which elevating the levels mechanisms by which elevating the levels of these neurotransmitters improves the of these neurotransmitters improves the psychological symptoms of anhedonia and psychological symptoms of anhedonia and poor social functioning remain unknown. poor social functioning remain unknown. Modelling the effects of antidepressants Modelling the effects of antidepressants in healthy volunteers without depression alin healthy volunteers without depression allows behavioural/neural differences in emolows behavioural/neural differences in emotional processing to be explored without tional processing to be explored without confounding by changes in symptom state. confounding by changes in symptom state. In addition, well-designed randomised conIn addition, well-designed randomised controlled studies with placebo comparison trolled studies with placebo comparison can be more readily undertaken. Thus, we can be more readily undertaken. Thus, we used functional magnetic resonance imaused functional magnetic resonance imaging (fMRI) to investigate emotional facial ging (fMRI) to investigate emotional facial processing in healthy volunteers randomprocessing in healthy volunteers randomised to receive either placebo or reboxetine ised to receive either placebo or reboxetine to test the specific prediction that reboxetine to test the specific prediction that reboxetine would reduce amygdala response to would reduce amygdala response to negative (fear) facial expressions. 
METHOD METHOD
Twenty-four healthy volunteers (see Table  Twenty -four healthy volunteers (see Table  DS2 .1 in data supplement 2 to the online DS2.1 in data supplement 2 to the online version of this paper) were screened to exversion of this paper) were screened to exclude current or past psychiatric disorder, clude current or past psychiatric disorder, substance misuse and contraindications for substance misuse and contraindications for fMRI. The study was approved by the local fMRI. The study was approved by the local ethics committee and written informed conethics committee and written informed consent was obtained. We used a double-blind, sent was obtained. We used a double-blind, randomised, placebo-controlled betweenrandomised, placebo-controlled betweengroup design with random allocation to group design with random allocation to either reboxetine (4 mg twice daily) or either reboxetine (4 mg twice daily) or placebo for 7 days. Subjective state was placebo for 7 days. Subjective state was recorded daily recorded daily throughout the study (for a throughout the study (for a complete list of measures used see Table  complete list of measures used see Table  DS2 .2 in online data supplement 2. DS2.2 in online data supplement 2.
On day 7 fMRI scans were acquired at On day 7 fMRI scans were acquired at 1.5 T (for details of acquisition and prepro-1.5 T (for details of acquisition and preprocessing see online data supplement 1). Facial cessing see online data supplement 1). Facial stimuli were prestimuli were presented in a block design. For the covert sented in a block design. For the covert task, four blocks each of fearful, happy task, four blocks each of fearful, happy and neutral faces were presented for 17 ms and neutral faces were presented for 17 ms and immediately masked with a neutral and immediately masked with a neutral face presented for 183 ms. For the overt face presented for 183 ms. For the overt task, four blocks each of fearful, happy task, four blocks each of fearful, happy and neutral faces were presented in isolaand neutral faces were presented in isolation (no mask) for 200 ms. Blocks were pretion (no mask) for 200 ms. Blocks were presented in random order for 20 s, with 10 sented in random order for 20 s, with 10 faces/face-mask pairs presented per block faces/face-mask pairs presented per block and each emotional block interspersed with and each emotional block interspersed with 20 s of fixation cross. For each facial pre-20 s of fixation cross. For each facial presentation volunteers were asked to judge sentation volunteers were asked to judge the gender of the face (gender discriminathe gender of the face (gender discrimination). Significant clusters were determined tion). Significant clusters were determined at a at a Z Z threshold of 2.7 ( threshold of 2.7 (P P¼0.05), corrected 0.05), corrected for the following four linear contrasts: for the following four linear contrasts: covert fear/happy covert fear/happy v.
v. covert neutral; overt covert neutral; overt fear/happy fear/happy v.
v. overt neutral. Subjective overt neutral. Subjective mood and anxiety were analysed using mood and anxiety were analysed using repeated-measures analysis of variance with repeated-measures analysis of variance with a4 a40.05 considered significant. 0.05 considered significant.
RESULTS RESULTS
Reboxetine did not affect subjective mood, Reboxetine did not affect subjective mood, although ratings of energy levels were inalthough ratings of energy levels were increased (see Table DS2 .2 in online data creased (see Table DS2 .2 in online data supplement 2). There were no significant supplement 2). There were no significant between-group differences in terms of genbetween-group differences in terms of gender discrimination or response time to corder discrimination or response time to correctly categorised faces in the scanner rectly categorised faces in the scanner ( (P P4 40.05 for all comparisons). Thus, differ-0.05 for all comparisons). Thus, differences in neural response can be explored in ences in neural response can be explored in the absence of significant between-group the absence of significant between-group differences in mood or overt differences in differences in mood or overt differences in behavioural performance measured during behavioural performance measured during scanning. scanning.
To examine amygdala response to fear To examine amygdala response to fear we extracted the percentage signal change we extracted the percentage signal change for left and right amygdala (Maldjian for left and right amygdala (Maldjian et et al al, 2003) from individuals ' unsmoothed , 2003 ) from individuals' unsmoothed fMRI time series. Using unsmoothed images fMRI time series. Using unsmoothed images took full advantage of the high-resolution took full advantage of the high-resolution data and limited blurring of activity from data and limited blurring of activity from adjacent structures. Right amygdala readjacent structures. Right amygdala response to covert fear was significantly sponse to covert fear was significantly attenuated under reboxetine (independent attenuated under reboxetine (independent measures, measures, t t 22 22 ¼2.3, 2.3, P P¼0.03; Fig. DS3 .1, on-0.03; Fig. DS3 .1, online data supplement 3). There were no line data supplement 3). There were no significant between-group differences to significant between-group differences to overt presentations of fear or to covert fear overt presentations of fear or to covert fear in left amygdala. in left amygdala.
Comparison of covert happy with Comparison of covert happy with covert neutral facial expressions revealed covert neutral facial expressions revealed greater activation under reboxetine in the greater activation under reboxetine in the right fusiform gyrus (Montreal Neuroright fusiform gyrus (Montreal Neurological Institute coordinates logical Institute coordinates x x¼44, 44, y y¼ 7 759, 59, z z¼7 720; Fig. DS3 .2, data supplement 20; Fig. DS3 .2, data supplement 3). To ensure that the effects of reboxetine 3). To ensure that the effects of reboxetine on task-specific brain activity are not on task-specific brain activity are not confounded by drug effect on baseline confounded by drug effect on baseline activation, the individual's percentage sigactivation, the individual's percentage signal change to covert happy and neutral nal change to covert happy and neutral faces was computed for the above cluster. faces was computed for the above cluster. Reboxetine significantly increased brain Reboxetine significantly increased brain activation to covert happy faces without activation to covert happy faces without affecting response to neutral faces (analysis affecting response to neutral faces (analysis of variance: expression of variance: expression6 6group interaction, group interaction, F F (1,22) ( Fig.  DS3 , data supplement 3.3). There were no DS3, data supplement 3.3). There were no significant between-group differences to significant between-group differences to covert fear covert fear v. v. covert neutral or for either covert neutral or for either overt comparisons. overt comparisons.
DISCUSSION DISCUSSION
Consistent with our hypothesis, short-term Consistent with our hypothesis, short-term treatment with reboxetine reduced treatment with reboxetine reduced amygdala activation to subliminal amygdala activation to subliminal negative negative facial expressions. We also saw increased facial expressions. We also saw increased 5 31 5 31 ( 2 0 0 7 ) , 1 9 0 , 5 3 1^5 3 2 . d o i : 1 0 .11 9 2 / b j p . b p .1 0 6 . 0 3 13 9 3 ( 2 0 0 7 ) , 1 9 0 , 5 3 1^5 3 2 . d o i : 1 0 .11 9 2 / b j p . b p .1 0 6 . 0 3 13 9 3 , 2004) . However, it is not known whether this normalisation of amygdala whether this normalisation of amygdala response with time is a direct effect of response with time is a direct effect of treatment or a marker of current symptom treatment or a marker of current symptom state. We suggest that, in healthy volunstate. We suggest that, in healthy volunteers, reboxetine has rapid and direct teers, reboxetine has rapid and direct effects on the amygdala response to sublimeffects on the amygdala response to subliminal fear, which are unconfounded by inal fear, which are unconfounded by changes in mood. changes in mood.
B R I T I S H J O UR N A L O F P S YC H I AT RY B R I T I S H J O UR N A L O F P SYC HI AT RY

S H O R T R E P O R T S H O R T R E P O R T
Notably, we saw decreased amygdala Notably, we saw decreased amygdala response to covert fear only, consistent with response to covert fear only, consistent with the hypothesis that antidepressants affect the hypothesis that antidepressants affect early automatic aspects of processing rather early automatic aspects of processing rather than strategic or elaborative stages. In line than strategic or elaborative stages. In line with this, data from animal studies suggest with this, data from animal studies suggest that noradrenaline inhibits cell firing in that noradrenaline inhibits cell firing in the basolateral amygdala (Aroniadouthe basolateral amygdala (AroniadouAnderjaska Anderjaska et al et al, 2006), a division of the , 2006), a division of the amygdala that, in humans, is activated by amygdala that, in humans, is activated by covert but not overt fearful stimuli (Etkin covert but not overt fearful stimuli (Etkin et al et al, 2004) . We have previously reported , 2004). We have previously reported a similar reduction in the amygdala fear a similar reduction in the amygdala fear response following 7-day treatment with response following 7-day treatment with citalopram (Harmer citalopram (Harmer et al et al, 2006) . These , 2006). These findings together with those of the present findings together with those of the present study suggest that two antidepressant comstudy suggest that two antidepressant compounds, putatively acting through different pounds, putatively acting through different neurochemical signalling mechanisms, have neurochemical signalling mechanisms, have similar rapid effects on fear processing in similar rapid effects on fear processing in the amygdala. These results are consistent the amygdala. These results are consistent with animal studies suggesting an inhibitory with animal studies suggesting an inhibitory effect of serotonin (Stutzmann & LeDoux, effect of serotonin (Stutzmann & LeDoux, 1999) and noradrenaline (Aroniadou-1999) and noradrenaline (AroniadouAnderjaska Anderjaska et al et al, 2006) on neuronal excit-, 2006) on neuronal excitability within the amygdala. These neural ability within the amygdala. These neural effects are also consistent with the behaveffects are also consistent with the behavioural reductions in fear recognition seen ioural reductions in fear recognition seen following short-term reboxetine and citalofollowing short-term reboxetine and citalopram administration (Harmer pram administration (Harmer et al et al, 2003 (Harmer et al et al, ). , 2003 . In addition, we observed increased acIn addition, we observed increased activation to subliminal tivation to subliminal positive positive faces in the faces in the right fusiform gyrus. We have suggested right fusiform gyrus. We have suggested that the facilitation of positive emotional that the facilitation of positive emotional processing is a general mechanism of action processing is a general mechanism of action of antidepressant drugs which is important of antidepressant drugs which is important to their therapeutic effects (Harmer to their therapeutic effects (Harmer et al et al, , 2004) . In depression, right fusiform activ-2004). In depression, right fusiform activation in response to happy faces is reduced ation in response to happy faces is reduced compared with healthy controls (Surguladze compared with healthy controls (Surguladze et al et al, 2005) , and modulation of activity in , 2005), and modulation of activity in this face processing sensory area has been this face processing sensory area has been suggested to contribute to changes in salsuggested to contribute to changes in salience of such emotional stimuli in attracting ience of such emotional stimuli in attracting attention (Vuilleumier, 2005) . As such, the attention (Vuilleumier, 2005) . As such, the increased response in the fusiform gyrus increased response in the fusiform gyrus specifically to happy facial expressions is specifically to happy facial expressions is consistent with our hypothesis and the beconsistent with our hypothesis and the behavioural increases in positive emotional havioural increases in positive emotional processing following reboxetine that have processing following reboxetine that have been reported previously (Harmer been reported previously (Harmer et al et al, , 2004) , as well as with the well charac-2004), as well as with the well characterised antidepressant effects of this drug terised antidepressant effects of this drug in clinical groups. in clinical groups.
A number of limitations to our study A number of limitations to our study should be noted. Although studies in should be noted. Although studies in healthy volunteers allow the assessment of healthy volunteers allow the assessment of drug effects unconfounded by changes in drug effects unconfounded by changes in clinical state, it remains to be tested clinical state, it remains to be tested whether similar effects occur in patients whether similar effects occur in patients with depression at this early stage in treatwith depression at this early stage in treatment and whether they are related to therament and whether they are related to therapeutic improvement. The present study was peutic improvement. The present study was also powered to detect differences in neural also powered to detect differences in neural responses to emotional stimuli rather than responses to emotional stimuli rather than changes in subjective mood. It is therefore changes in subjective mood. It is therefore possible that subtle changes in mood might possible that subtle changes in mood might accompany these changes in neural reaccompany these changes in neural responses which we could not detect. Further sponses which we could not detect. Further studies using larger samples are therefore studies using larger samples are therefore needed to test whether these effects are needed to test whether these effects are truly independent. truly independent.
Our finding of reduced amygdala reOur finding of reduced amygdala response to fear was also seen in an indepensponse to fear was also seen in an independent sample following administration of the dent sample following administration of the selective serotonin reuptake inhibitor citaselective serotonin reuptake inhibitor citalopram, suggesting that this effect might relopram, suggesting that this effect might represent a common downstream action of present a common downstream action of effective pharmacological treatment for deeffective pharmacological treatment for depression. However, there were also some pression. However, there were also some differences in these effects: namely the indifferences in these effects: namely the increased fusiform gyrus response to happy creased fusiform gyrus response to happy facial expressions following reboxetine facial expressions following reboxetine and the decreased hippocampal and medial and the decreased hippocampal and medial prefrontal cortex response to fear following prefrontal cortex response to fear following citalopram. Further studies are required to citalopram. Further studies are required to directly compare the profile of effect directly compare the profile of effect produced by selective serotonin and norproduced by selective serotonin and noradrenaline reuptake inhibitors on emotional adrenaline reuptake inhibitors on emotional processing to examine whether there are processing to examine whether there are distinct as well as overlapping effects. distinct as well as overlapping effects.
